John Trizzino - Novavax Senior Vice President - Commercial Operations
| NVAX Stock | USD 4.19 0.12 2.95% |
President
Mr. John J. Trizzino is Senior Vice President, Chief Business Officer, Chief Financial Officer and Treasurer of Novavax, Inc. He previously served as the Companys Senior Vice President, Business Development from August 2010 to September 2011, and its Senior Vice President, International and Government Alliances from July 2009 to July 2010. Prior to joining the Company, Mr. Trizzino was the CEO of Immunovaccine from September 2011 to September 2013, VP, Vaccine Franchise at Medimmune, LLC, Senior Vice President, Business Development at ID Biomedical, and Vice President, Business Development in the Medical Group of Henry Schein, Inc. following his position as Vice President, General Manager of its GIV division. Mr. Trizzino also serves on the board of directors of The Maryland Tech Council since 2018.
| Age | 57 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878 |
| Phone | 240 268 2000 |
| Web | https://www.novavax.com |
John Trizzino Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Trizzino against Novavax stock is an integral part of due diligence when investing in Novavax. John Trizzino insider activity provides valuable insight into whether Novavax is net buyers or sellers over its current business cycle. Note, Novavax insiders must abide by specific rules, including filing SEC forms every time they buy or sell Novavax'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Trizzino over six months ago Exercise or conversion by John Trizzino of 833 shares of Novavax subject to Rule 16b-3 |
Novavax Management Efficiency
The company has return on total asset (ROA) of (0.1702) % which means that it has lost $0.1702 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.982) %, meaning that it created substantial loss on money invested by shareholders. Novavax's management efficiency ratios could be used to measure how well Novavax manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.30 in 2024, whereas Return On Tangible Assets are likely to drop (0.33) in 2024. At this time, Novavax's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 747 M in 2024, whereas Other Current Assets are likely to drop slightly above 191.7 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Paul Hudson | AstraZeneca PLC ADR | N/A | |
| Iskra Reic | AstraZeneca PLC ADR | N/A | |
| Leon Wang | AstraZeneca PLC ADR | N/A | |
| Ruud Dobber | AstraZeneca PLC ADR | N/A | |
| Luke Miels | AstraZeneca PLC ADR | N/A | |
| Sean Bohen | AstraZeneca PLC ADR | N/A | |
| Mark Colonnese | Vaxart Inc | 60 | |
| Pam Cheng | AstraZeneca PLC ADR | 54 | |
| Menelas Pangalos | AstraZeneca PLC ADR | 57 | |
| Bahija Jallal | AstraZeneca PLC ADR | 55 | |
| Jose Baselga | AstraZeneca PLC ADR | 58 | |
| Mark Mallon | AstraZeneca PLC ADR | N/A | |
| Katarina Ageborg | AstraZeneca PLC ADR | N/A | |
| Fiona Cicconi | AstraZeneca PLC ADR | N/A | |
| David Fredrickson | AstraZeneca PLC ADR | N/A | |
Management Performance
| Return On Equity | -8.98 | ||||
| Return On Asset | -0.17 |
Novavax Leadership Team
Elected by the shareholders, the Novavax's board of directors comprises two types of representatives: Novavax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novavax. The board's role is to monitor Novavax's management team and ensure that shareholders' interests are well served. Novavax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novavax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, President COO | ||
| Jody Lichaa, Vice President - Quality Assurance | ||
| Michael McManus, Independent Director | ||
| Barclay Phillips, CFO, Sr. VP and Treasurer | ||
| Stanley Erck, CEO and President Director and Member of Fin. Committee | ||
| Russell JD, Sr. VP of Bus. Devel. | ||
| Mark Casey, Chief VP | ||
| Brian Webb, Vice President Manufacturing | ||
| Jeffrey Stoddard, Vice President - Medical Affairs | ||
| Louis Fries, Vice President Chief Medical Officer | ||
| John Herrmann, Senior Vice President General Counsel, Corporate Secretary | ||
| Rachel King, Director | ||
| Gary Evans, Independent Director | ||
| Nigel Thomas, Vice President - Clinical Operations | ||
| Silvia MBA, Executive Officer | ||
| Erika Trahan, Associate Relations | ||
| John MBA, CEO Director | ||
| Iksung Cho, Vice President - Biostatistics | ||
| Susan Hensley, Vice President Regulatory Operations | ||
| James CFA, CFO VP | ||
| Rajiv Modi, Director | ||
| John Trizzino, Senior Vice President - Commercial Operations | ||
| Timothy Hahn, Sr. VP of Global Manufacturing Operations | ||
| Chris Dunne, Vice President - Finance | ||
| JD Esq, Senior Officer | ||
| Brian Rosen, Senior Vice President - Commercial Strategy | ||
| Amy Fix, Senior Vice President - Regulatory Affairs | ||
| Mark Twyman, Vice President of Marketing | ||
| Richard Crowley, Executive COO | ||
| Ian Watkins, Executive Officer | ||
| Russell Wilson, Senior Vice President - Business Development | ||
| John III, Chief VP | ||
| Biegie Lee, VP Officer | ||
| Bob Darius, Senior Vice President - Quality Operations | ||
| Gale Smith, VP Scientist | ||
| James Young, Independent Chairman of the Board | ||
| Gregory Glenn, Senior Vice President - Research & Development | ||
| Gail Boudreaux, Director | ||
| James Cummings, Vice President - Clinical Development and Translational Medicine | ||
| Richard Douglas, Independent Director | ||
| Kathleen Callahan, Vice President Regulatory Affairs, CMC |
Novavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novavax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.98 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.55) % | ||||
| Operating Margin | (0.63) % | ||||
| Current Valuation | 281.74 M | ||||
| Shares Outstanding | 139.95 M | ||||
| Shares Owned By Insiders | 4.99 % | ||||
| Shares Owned By Institutions | 57.43 % | ||||
| Number Of Shares Shorted | 43.91 M | ||||
| Price To Earning | (1.36) X |
Novavax Investors Sentiment
The influence of Novavax's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novavax. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novavax's public news can be used to forecast risks associated with an investment in Novavax. The trend in average sentiment can be used to explain how an investor holding Novavax can time the market purely based on public headlines and social activities around Novavax. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novavax's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novavax's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novavax's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novavax.
Novavax Implied Volatility | 94.16 |
Novavax's implied volatility exposes the market's sentiment of Novavax stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Novavax's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Novavax stock will not fluctuate a lot when Novavax's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novavax in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novavax's short interest history, or implied volatility extrapolated from Novavax options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.41) | Revenue Per Share 9.762 | Quarterly Revenue Growth (0.18) | Return On Assets (0.17) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.